Summary
Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler's health, child's health, and pet's health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.
History
Pivot Pharmaceuticals is a publicly traded biopharmaceutical company that was founded in 2015. The company was formed to acquire and develop commercially viable products within the pharamaceutical and nutraceutical industry, leveraging its delivery and safety platform technologies.
Mission
Our mission is to develop novel, safe and less polluting drugs, health products and technologies that can improve the well-being of those suffering from diverse conditions, utilizing innovative drug delivery technologies.
Vision
Our vision is to be one of the global leaders in the development and commercialization of pharmaceuticals and nutraceuticals.
Key Team
Ms. Rachelle MacSweeney (Co-Founder, CEO, Pres & Director)
Mr. George Jackowski (Co-Founder, Chief Scientific Officer & Director)
Recognition and Awards
Pivot has been recognized with numerous awards and accolades, including the 2019 British Columbia Technology Innovation Award and the 2015 Top 10 Most Innovative Companies Award.
References
